Improving Clinical Recognition of HCM: The Pursuit of Accurate Diagnosis
-
- Putting a clinical spotlight on HCM case studies
- Clinical Management of Hypertrophic Cardiomyopathy
- Improving Clinical Recognition of HCM
- Sudden Cardiac Death Prevention in HCM: Where Do We Stand in 2021?
- Imaging for the Diagnosis and Management of HCM
- Clinical Implications of Genetic Testing in HCM
- HCM: An Introduction and Overview
-
- Putting a clinical spotlight on HCM case studies
- Clinical Management of Hypertrophic Cardiomyopathy
- Improving Clinical Recognition of HCM
- Sudden Cardiac Death Prevention in HCM: Where Do We Stand in 2021?
- Imaging for the Diagnosis and Management of HCM
- Clinical Implications of Genetic Testing in HCM
- HCM: An Introduction and Overview
Improving Clinical Recognition of HCM: The Pursuit of Accurate Diagnosis
Presenters: Matthew Martinez, MD, FACC; Anjali Tiku Owens, MD; Sharon Cresci, MD, FAHA, FACC, FASE
Moderator: James E. Udelson, MD, FAHA
HCM is a chronic disease that can progress to cardiac dysfunction and the clinical syndrome of heart failure. It is estimated that 1 in every 500 adults living in the U.S. have HCM, but a large percentage of patients are undiagnosed. Which of your patients is undiagnosed?
Bristol Myers Squibb is a national sponsor of the American Heart Association’s hypertrophic cardiomyopathy initiative.
Matthew Martinez, MD, FACC
Director of Atlantic Health System Sports Cardiology, Morristown Medical Center
Anjali Tiku Owens, MD
Assistant Professor of Medicine
University of Pennsylvania
Sharon Cresci, MD, FAHA, FACC, FASE
Cardiovascular Division Associate Professor of Medicine, Associate Professor of Genetics, Washington University School of Medicine in St. Louis
Dr. James E. Udelson, MD, FAHA
Chief, Division of Cardiology,
Tufts Medical Center